BioCardia Reaches Full Compliance with Nasdaq Listing Standards
BioCardia, Inc. has made impressive strides by achieving full compliance with the Nasdaq Capital Market's listing standards. This accomplishment came after a favorable ruling from the Hearing Panel of Nasdaq.
Notification of Compliance from Nasdaq
Recently, BioCardia received formal confirmation from Nasdaq regarding its adherence to Listing Rule 5550(b)(1), commonly referred to as the Equity Rule. The Panel has opted to keep the company’s securities listed on the Nasdaq Stock Market, effectively resolving the compliance issue.
Strengthening Financial Health
This noteworthy achievement follows BioCardia's dedicated efforts to improve its balance sheet. The company has successfully raised additional capital to support the ongoing development of its therapeutic candidates, ensuring its approved products progress toward market approval.
FDA Approvals and Progress
One of the standout moments recently was the FDA's approval of the CardiAMP Cell Therapy Heart Failure II protocol amendment. This development utilizes the proprietary Cell Population Analysis screening tool to tailor treatment strategies for patients, highlighting BioCardia's commitment to personalized medicine.
Advancing Clinical Trials
In addition, the University of Wisconsin has completed treatment for the last patient enrolled in the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial. Furthermore, Helix™ partner CellProthera has recently had a productive pre-IND meeting with the FDA, setting the stage for new advancements in acute myocardial infarction cell therapy.
Future Initiatives and Market Growth
Peter Altman, PhD, who serves as the President and CEO of BioCardia, expressed strong optimism regarding the company's future. BioCardia has achieved FDA market clearance for its Morph DNA product family and has successfully concluded a $7.2 million financing round aimed at enhancing its research and development efforts.
Commitment to Cardiovascular Health
BioCardia remains steadfast in its mission to advance therapies targeting cardiovascular and pulmonary diseases. Their immediate priorities include finalizing data from the CardiAMP HF I trial for both the Japan PMDA and FDA review, while also commencing patient randomization for the pivotal CardiAMP HF II trial.
About BioCardia
Based in Sunnyvale, California, BioCardia is a leader in developing cellular and cell-derived therapeutics for treating cardiovascular and pulmonary diseases. The company's biotherapeutic platforms feature the autologous CardiAMP and allogeneic CardiALLO cell therapies, with three product candidates currently in clinical development.
These groundbreaking therapies are further supported by BioCardia's Helix biotherapeutic delivery and Morph vascular navigation product platforms, designed to improve treatment efficacy.
Frequently Asked Questions
What does BioCardia specialize in?
BioCardia focuses on developing cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary conditions.
What recent compliance has BioCardia achieved?
BioCardia has regained full compliance with the Nasdaq Capital Market's listing standards, allowing its securities to remain listed.
What FDA approvals has BioCardia obtained?
BioCardia has secured FDA approval for the CardiAMP Cell Therapy Heart Failure II protocol amendment and received market clearance for its Morph DNA products.
How is BioCardia improving its financial health?
The company has successfully raised additional capital through financing rounds to advance its therapeutic development and enhance its product offerings.
What are BioCardia’s future plans?
BioCardia plans to conclude data analysis from the CardiAMP HF I trial and start the pivotal CardiAMP HF II trial while continuing to support its partners in therapeutic developments.
